Experimental HCV Drugs
Experimental HCV Drugs
Coverage of IDWeek 2014
- Details
- Category: HIV Treatment
- Published on Friday, 17 October 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.
Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.
Full listing of coverage by topic
10/17/14
IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 15 October 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.
Simeprevir as Effective, Better Tolerated than Telaprevir in HCV Triple Therapy
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 10 October 2014 00:00
- Written by Janssen
The recently approved next-generation hepatitis C virus (HCV) protease inhibitor simeprevir (Olysio) produced sustained virological response rates similar to those of telaprevir (Incivek or Incivo) when combined with pegylated interferon and ribavirin, but with fewer side effects, researchers reported at theViral Hepatitis Congress taking place this week in Frankfurt.
IDWeek 2014: Sofosbuvir/Ledipasvir Safe and Effective for Genotype 1 HCV
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 15 October 2014 00:00
- Written by Liz Highleyman
A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir -- the combination in Gilead Science's recently approved Harvoni pill -- was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, researchers reported at the IDWeek 2014 meeting last week in Philadelphia.
FDA Approves Harvoni, Gilead's Sofosbuvir/Ledipasvir Combo Pill for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 10 October 2014 00:00
- Written by HIVandHepatitis.com
On October 10, the U.S. Food and Drug Administration (FDA) approved a new once-daily combination pill for the treatment of genotype 1 chronic hepatitis C containing Gilead Sciences' HCV nucleotide polymerase inhibitor sofosbuvir (Sovaldi) plus ledipasvir, the first approved HCV NS5A inhibitor.
More Articles...
- BMS Withdraws FDA Application for Hepatitis C Drug Asunaprevir
- Sofosbuvir + Ribavirin To Be Studied in Children and Adolescents with Hepatitis C
- ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials
- Coverage of the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy
Web Design and Development by